Thus, by modulating the interaction between CD40 on tumor cells and CD40L on activated T cells, the efficiency of cancer immunotherapy could be increased by regulating the TGF-β production in a tumor microenvironment. This evidence concerns the gene TGFB1 and neoplasm.